161735-79-1 | Rasagiline mesylate

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$13.00	$9.00
50mg	97%	in stock	$17.00	$12.00
1g	97%	in stock	$47.00	$33.00
5g	97%	in stock	$139.00	$97.00
10g	97%	in stock	$235.00	$165.00
25g	97%	in stock	$449.00	$315.00
100g	97%	in stock	$1,505.00	$1,054.00

Description

• Catalog Number: AA87734
• Chemical Name: Rasagiline mesylate
• CAS Number: 161735-79-1
• Molecular Formula: C13H17NO3S
• Molecular Weight: 267.34398000000004
• MDL Number: MFCD08460604
• SMILES: CS(=O)(=O)O.C#CCN[C@@H]1CCc2c1cccc2

Computed Properties

• Complexity: 305
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2

Literature

• Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.

  International journal of pharmaceutics 20121115

• Rasagiline: a guide to its use in Parkinson's disease.

  CNS drugs 20120901

• Proteoliposome-based capillary electrophoresis for screening membrane protein inhibitors.

  Journal of chromatographic science 20120801

• Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.

  The International journal of neuroscience 20120701

• Drugs for treating Parkinson disease.

  Nursing 20120701

• Development of Parkinson's disease in patients with Narcolepsy.

  Journal of neural transmission (Vienna, Austria : 1996) 20120601

• Hyposmia in Parkinson's disease.

  Psychiatry and clinical neurosciences 20120601

• Livedo reticularis associated with rasagiline (azilect).

  Journal of drugs in dermatology : JDD 20120601

• The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

  Journal of clinical pharmacology 20120501

• Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).

  Bioorganic & medicinal chemistry 20120501

• Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

  Journal of neural transmission (Vienna, Austria : 1996) 20120401

• Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

  Drugs 20120326

• Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.

  Retina (Philadelphia, Pa.) 20120301

• Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

  European journal of neurology 20120201

• From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• Restless legs syndrome responsive to rasagiline treatment: a case report.

  Clinical neuropharmacology 20120101

• Combined beneficial effect of rasagiline on motor function and depression in de novo PD.

  Clinical neuropharmacology 20120101

• Drugs in traffic: the road to approval.

  Nature medicine 20111206

• Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

  European journal of neurology 20111201

• Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.

  Movement disorders : official journal of the Movement Disorder Society 20111201

• Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.

  European journal of pharmacology 20111130

• Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.

  Movement disorders : official journal of the Movement Disorder Society 20111101

• Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

  The neurologist 20111101

• An effective novel delivery strategy of rasagiline for Parkinson's disease.

  International journal of pharmaceutics 20111031

• Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

  The International journal of neuroscience 20110901

• The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.

  Movement disorders : official journal of the Movement Disorder Society 20110815

• Safety of rasagiline for the treatment of Parkinson's disease.

  Expert opinion on drug safety 20110701

• TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.

  Circulation. Heart failure 20110701

• The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.

  British journal of pharmacology 20110601

• Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.

  Expert opinion on pharmacotherapy 20110601

• A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

  The Lancet. Neurology 20110501

• MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.

  Journal of proteome research 20110401

• Determination of minimal clinically important change in early and advanced Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20110401

• Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

  Antioxidants & redox signaling 20110301

• Hemiparkinsonism-hemiatrophy syndrome.

  Archives of Iranian medicine 20110301

• Rasagiline-induced serotonin syndrome.

  Movement disorders : official journal of the Movement Disorder Society 20110301

• Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.

  Drugs & aging 20110201

• MAO inhibitors.

  Cleveland Clinic journal of medicine 20110201

• Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.

  Journal of glaucoma 20110101

• Selegiline and rasagiline: twins or distant cousins?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110101

• Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.

  BMC pharmacology 20110101

• Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

  Current medicinal chemistry 20110101

• [The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20110101

• Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

  International review of neurobiology 20110101

• Rasagiline in Parkinson's disease.

  International review of neurobiology 20110101

• Selective inhibitors of monoamine oxidase type B and the 'cheese effect'.

  International review of neurobiology 20110101

• Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.

  Journal of clinical pharmacology 20101201

• Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

  Neurochemical research 20101201

• The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20101123

• The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20101123

• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  Progress in neurobiology 20101101

• Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.

  Neurochemistry international 20101101

• [Rasagiline: effectiveness and protection in Parkinson's disease].

  Revista de neurologia 20101101

• [Disease-modifying therapies in PD].

  Rinsho shinkeigaku = Clinical neurology 20101101

• Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.

  European journal of neurology 20100901

• Isolated delusional syndrome in Parkinson's Disease.

  Parkinsonism & related disorders 20100901

• Slowing the decline.

  Nature 20100826

• Rasagiline improves learning and memory in young healthy rats.

  Behavioural pharmacology 20100701

• Discordant effects of rasagiline doses in Parkinson disease.

  Nature reviews. Neurology 20100701

• Long-term efficacy of rasagiline in early Parkinson's disease.

  The International journal of neuroscience 20100601

• Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

  Neurology 20100406

• The delayed-start study in Parkinson disease: can't satisfy everyone.

  Neurology 20100406

• Reply to Drs. Olanow and Rascol.

  Neurology 20100406

• The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.

  Journal of neurochemistry 20100301

• [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].

  Fortschritte der Neurologie-Psychiatrie 20100301

• Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.

  Nature reviews. Neurology 20100301

• Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.

  The American journal of managed care 20100301

• Rasagiline in Parkinson's disease.

  The New England journal of medicine 20100218

• Rasagiline in Parkinson's disease.

  The New England journal of medicine 20100218

• TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.

  The Journal of pharmacology and experimental therapeutics 20100201

• Selective MAO-B inhibitors have low potential for the tyramine effect.

  Movement disorders : official journal of the Movement Disorder Society 20100115

• Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.

  Neuro-degenerative diseases 20100101

• The role of rasagiline in the treatment of Parkinson's disease.

  Clinical interventions in aging 20100101

• What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?

  Neuroepidemiology 20100101

• Delayed start, rapid solution?

  Neuroepidemiology 20100101

• Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.

  Neuropsychobiology 20100101

• Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

  Clinical drug investigation 20100101

• [Rasagiline is not for all Parkinson disease patients: the ADAGIO study].

  Nederlands tijdschrift voor geneeskunde 20100101

• [Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• Mao-B inhibitor know-how: back to the pharm.

  Neurology 20091208

• Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram.

  Progress in neuro-psychopharmacology & biological psychiatry 20091113

• Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

  Journal of neural transmission (Vienna, Austria : 1996) 20091101

• Rasagiline-induced spontaneous ejaculation.

  Movement disorders : official journal of the Movement Disorder Society 20091030

• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  The New England journal of medicine 20090924

• Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan.

  Neurotoxicity research 20090801

• Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres.

  Journal of pharmaceutical and biomedical analysis 20090712

• Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090415

• MAO-B inhibitor know-how: back to the pharm.

  Neurology 20090414

• Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

  Neurotoxicity research 20090401

• Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20090315

• Neuroprotection by rasagiline in thiamine deficient rats.

  Brain research 20090223

• Mechanisms compensating for dopamine loss in early Parkinson disease.

  Neurology 20090217

• [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].

  Ideggyogyaszati szemle 20090130

• Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20090101

• Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.

  European review for medical and pharmacological sciences 20090101

• [Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.

  Drugs & aging 20090101

• Sleep attack associated to rotigotine.

  Clinical neuropharmacology 20090101

• Drug selection and timing of initiation of treatment in early Parkinson's disease.

  Annals of neurology 20081201

• A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

  Movement disorders : official journal of the Movement Disorder Society 20081115

• Rapid and sensitive liquid chromatography-tandem mass spectrometry: assay development, validation and application to a human pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115

• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

  Expert opinion on pharmacotherapy 20081101

• Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).

  Acta crystallographica. Section C, Crystal structure communications 20081101

• Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081001

• [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

  Fortschritte der Neurologie-Psychiatrie 20081001

• Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.

  Hypertension (Dallas, Tex. : 1979) 20080901

• TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.

  Journal of cardiovascular pharmacology 20080901

• Rasagiline in neurodegeneration.

  Experimental neurology 20080801

• Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.

  Journal of neurochemistry 20080601

• [Rasagiline in Parkinson's disease].

  Neurologia (Barcelona, Spain) 20080501

• Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.

  Experimental neurology 20080401

• [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20080301

• Rasagiline improves freezing in a patient with primary progressive freezing gait.

  Movement disorders : official journal of the Movement Disorder Society 20080215

• Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.

  Journal of biomolecular structure & dynamics 20080201

• Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20080101

• [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20080101

• Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

  Pharmacotherapy 20071201

• Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.

  Annals of the New York Academy of Sciences 20071201

• Parkinson disease: an incremental challenge.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20071201

• Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.

  Journal of neurochemistry 20071001

• Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway.

  Neurochemical research 20071001

• Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

  Clinical therapeutics 20070901

• The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

  Molecular pharmacology 20070601

• Rasagiline as a therapy for Parkinson's disease (PD).

  The American journal of geriatric pharmacotherapy 20070601

• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  Neurobiology of disease 20070101

• Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• Rasagiline: a review of its use in the management of Parkinson's disease.

  Drugs 20070101

• Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

  Drugs & aging 20070101

• Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.

  Journal of neural transmission. Supplementum 20070101

• Rasagiline (Azilect) for Parkinson's disease.

  The Medical letter on drugs and therapeutics 20061204

• L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.

  Pharmacology, biochemistry, and behavior 20061201

• The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

  Current Alzheimer research 20061201

• Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

  The American journal of geriatric pharmacotherapy 20061201

• Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

  Journal of the neurological sciences 20061025

• Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.

  Neurology 20060523

• Clinical trials with rasagiline: evidence for short-term and long-term effects.

  Neurology 20060523

• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515

• [Diagnosis and therapy of idiopathic Parkinson's disease].

  MMW Fortschritte der Medizin 20060515

• Safety of rasagiline in elderly patients with Parkinson disease.

  Neurology 20060509

• Rasagiline improves quality of life in patients with early Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20060501

• Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

  The Annals of pharmacotherapy 20060401

• Rasagiline -- is there a place for this drug in managing Parkinson's disease?

  International journal of clinical practice 20060201

• Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.

  International journal of clinical practice 20060201

• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.

  British journal of pharmacology 20060101

• Concerning neuroprotective therapy for Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.

  Journal of neural transmission. Supplementum 20060101

• New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate.

  Journal of the American Pharmacists Association : JAPhA 20060101

• New drug treatment for Parkinson's disease.

  FDA consumer 20060101

• Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.

  Journal of neural transmission. Supplementum 20060101

• The use of rasagiline in Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.

  Journal of medicinal chemistry 20051229

• Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20051101

• Present and future drug treatment for Parkinson's disease.

  Journal of neurology, neurosurgery, and psychiatry 20051101

• Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

  Expert review of neurotherapeutics 20051101

• Rasagiline in the pharmacotherapy of Parkinson's disease--a review.

  Expert opinion on pharmacotherapy 20051001

• In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20051001

• [Rasagiline in motor fluctuations].

  Fortschritte der Neurologie-Psychiatrie 20050901

• Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.

  Journal of neural transmission (Vienna, Austria : 1996) 20050801

• Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.

  Journal of clinical pharmacology 20050801

• Reexamination of the TEMPO Study.

  Archives of neurology 20050801

• Rasagiline.

  Nature reviews. Drug discovery 20050801

• Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.

  Annals of the New York Academy of Sciences 20050801

• [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].

  Medizinische Monatsschrift fur Pharmazeuten 20050701

• Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.

  Drugs of today (Barcelona, Spain : 1998) 20050601

• Parkinson's disease. Diagnosis and the initiation of therapy.

  Minerva medica 20050601

• Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

  Movement disorders : official journal of the Movement Disorder Society 20050501

• Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.

  Brain research. Brain research reviews 20050401

• Novel pharmacological strategies for motor complications in Parkinson's disease.

  Expert opinion on investigational drugs 20050401

• Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.

  Neuropharmacology 20050301

• Rasagiline for motor complications in Parkinson's disease.

  Lancet (London, England) 20050301

• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  Lancet (London, England) 20050301

• Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

  Mechanisms of ageing and development 20050201

• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

  Archives of neurology 20050201

• Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

  Journal of neuroscience research 20050101

• Movement disorders: understanding clinical trials.

  The Lancet. Neurology 20050101

• Rasagiline.

  Drugs & aging 20050101

• Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.

  Movement disorders : official journal of the Movement Disorder Society 20050101

• Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

  CNS drug reviews 20050101

• [The early therapy challenge].

  Krankenpflege Journal 20050101

• [Are there innovations in the treatment of Parkinson's disease?].

  Praxis 20041103

• Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.

  Neurology 20041012

• Clinical trials of neuroprotection for Parkinson's disease.

  Neurology 20041012

• Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

  British journal of pharmacology 20041001

• Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.

  Pharmacotherapy 20041001

• Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040901

• Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.

  Journal of neurology 20040901

• Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.

  Movement disorders : official journal of the Movement Disorder Society 20040801

• Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.

  Neuropharmacology 20040701

• Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.

  Experimental neurology 20040601

• Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.

  Journal of neurochemistry 20040601

• N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.

  Neurochemistry international 20040501

• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  Archives of neurology 20040401

• Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.

  Journal of medicinal chemistry 20040325

• Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.

  Journal of medicinal chemistry 20040325

• Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

  Neuroscience letters 20040130

• Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?

  BioEssays : news and reviews in molecular, cellular and developmental biology 20040101

• The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031201

• The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

  Biochemical pharmacology 20031015

• Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

  Annals of the New York Academy of Sciences 20030501

• Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.

  Journal of enzyme inhibition and medicinal chemistry 20030401

• Monoamine oxidase inhibitors--is it time to up the TEMPO?

  The Lancet. Neurology 20030301

• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  Archives of neurology 20021201

• Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.

  Neuropharmacology 20021201

• Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021001

• Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.

  Journal of neurochemistry 20020801

• Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

  Movement disorders : official journal of the Movement Disorder Society 20020701

• An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells.

  Neuroscience letters 20020628

• Rasagiline. Teva Pharmaceutical.

  Current opinion in investigational drugs (London, England : 2000) 20020501

• Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines.

  Journal of neural transmission (Vienna, Austria : 1996) 20020501

• Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.

  Mechanisms of ageing and development 20020430

• The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.

  Journal of neural transmission (Vienna, Austria : 1996) 20020401

• Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.

  Parkinsonism & related disorders 20020301

• Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

  Cellular and molecular neurobiology 20011201

• Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.

  Journal of neurochemistry 20010801

• Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.

  Annals of the New York Academy of Sciences 20010601

• Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

  Annals of the New York Academy of Sciences 20010601

• The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.

  Annals of the New York Academy of Sciences 20010601

• Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.

  Annals of the New York Academy of Sciences 20010401

• Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

  British journal of pharmacology 20010101

• Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.

  Journal of neural transmission. Supplementum 19980101